Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
PLOS Pathogens · 29.06.2023 · 19 (6) · e1011469
DOI: 10.1371/journal.ppat.1011469 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 29.06.2023. Verfasst von Nonhlanhla N Mkhize und 39 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, HIV Seropositivity. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation.
Abstract (Originalsprache)
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against bnAb-sensitive viruses. HIV-1 viruses isolated from AMP participants who acquired infection during the study in the sub-Saharan African (HVTN 703/HPTN 081) and the Americas/European (HVTN 704/HPTN 085) trials represent a panel of currently circulating strains of HIV-1 and offer a unique opportunity to investigate the sensitivity of the virus to broadly neutralizing antibodies (bnAbs) being considered for clinical development. Pseudoviruses were constructed using envelope sequences from 218 individuals. The majority of viruses identified were clade B and C; with clades A, D, F and G and recombinants AC and BF detected at lower frequencies. We tested eight bnAbs in clinical development (VRC01, VRC07-523LS, 3BNC117, CAP256.25, PGDM1400, PGT121, 10–1074 and 10E8v4) for neutralization against all AMP placebo viruses (n = 76). Compared to older clade C viruses (1998–2010), the HVTN703/HPTN081 clade C viruses showed increased resistance to VRC07-523LS and CAP256.25. At a concentration of 1μg/ml (IC80), predictive modeling identified the triple combination of V3/V2-glycan/CD4bs-targeting bnAbs (10-1074/PGDM1400/VRC07-523LS) as the best against clade C viruses and a combination of MPER/V3/CD4bs-targeting bnAbs (10E8v4/10-1074/VRC07-523LS) as the best against clade B viruses, due to low coverage of V2-glycan directed bnAbs against clade B viruses. Overall, the AMP placebo viruses represent a valuable resource for defining the sensitivity of contemporaneous circulating viral strains to bnAbs and highlight the need to update reference panels regularly. Our data also suggests that combining bnAbs in passive immunization trials would improve coverage of global viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
- SA MRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Institute for Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
- South African Medical Research Council Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences University of the Witwatersrand, Johannesburg, South Africa.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Nonhlanhla N Mkhize, Amanda S Woodward Davis, Lynn Morris
Förderung
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation
- Bill & Melinda Gates Foundation’s Collaboration for AIDS Vaccine Discovery
Zitieren
APA
Mkhize, N. N., Yssel, A. E. J., Kaldine, H., van Dorsten, R. T., Woodward Davis, A. S., Beaume, N., Matten, D., Lambson, B., Modise, T., Kgagudi, P., York, T., Westfall, D. H., Giorgi, E. E., Korber, B., Anthony, C., Mapengo, R. E., Bekker, V., Domin, E., Eaton, A., …, & Morris, L. (2023). Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLOS Pathogens, 19(6), e1011469. https://doi.org/10.1371/journal.ppat.1011469
Vancouver
Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, et al. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLOS Pathogens. 2023;19(6):e1011469. doi:10.1371/journal.ppat.1011469
BibTeX
@article{Mkhize2023,
author = {Mkhize, Nonhlanhla N and Yssel, Anna E J and Kaldine, Haajira and van Dorsten, Rebecca T and Woodward Davis, Amanda S and Beaume, Nicolas and Matten, David and Lambson, Bronwen and Modise, Tandile and Kgagudi, Prudence and York, Talita and Westfall, Dylan H and Giorgi, Elena E and Korber, Bette and Anthony, Colin and Mapengo, Rutendo E and Bekker, Valerie and Domin, Elizabeth and Eaton, Amanda and Deng, Wenjie and DeCamp, Allan and Huang, Yunda and Gilbert, Peter B and Gwashu-Nyangiwe, Asanda and Thebus, Ruwayhida and Ndabambi, Nonkululeko and Mielke, Dieter and Mgodi, Nyaradzo and Karuna, Shelly and Edupuganti, Srilatha and Seaman, Michael S and Corey, Lawrence and Cohen, Myron S and Hural, John and McElrath, M Juliana and Mullins, James I and Montefiori, David and Moore, Penny L and Williamson, Carolyn and Morris, Lynn},
title = {Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials},
journal = {PLOS Pathogens},
year = {2023},
volume = {19},
number = {6},
pages = {e1011469},
doi = {10.1371/journal.ppat.1011469}
}
EUVIMED